Remission · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) All… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to achieve 12‐month remission (seizure‐free period) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to 12‐month remission ‐ stratified by epilepsy type ‐ Generalized onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Behavioural problems: agitation or aggression · people with agitation in dementia
3 findings from 1 review
no estimate extracted
2 studies · 202 participants
Moderate
no estimate extracted
2 studies · 202 participants
Moderate
no estimate extracted
3 studies · 217 participants
Very low
Cognitive function · people with agitation in dementia
1 finding from 1 review
Functional performance · people with agitation in dementia
1 finding from 1 review
Any adverse event by 6 weeks · people with agitation in dementia
Valproate preparations may leads to higher any adverse event by 6 weeks compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events by 6 weeks · people with agitation in dementia
It is very uncertain whether valproate preparations changes serious adverse events by 6 weeks compared with placebo (very low certainty).
1 finding from 1 review
Response to treatment (medium term) Clinically important response to treatment as defined by each study · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS may leads to higher clinically significant response: important change As defined by each… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
It is very uncertain whether VALPROATE + ANTIPSYCHOTICS changes leaving the study early: Acceptability of treatment Leaving the… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (very low certainty).
1 finding from 1 review
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS showed no clear difference in leaving the study early: Overall tolerability Leaving the study… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Behavioural problems: agitation or aggression · patients with schizophrenia
1 finding from 1 review
Adverse effects: 1. Sedation · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS may leads to higher adverse events: Sedation Number of participants with… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS showed no clear difference in adverse events: Weight gain Number of participants with weight gain compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
1 finding from 1 review
Seizure freedom · participants with generalised epilepsy
Summary of findings: needle acupuncture plus valproate showed no clear difference in seizure freedom ( compared with valproate alone (moderate certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · participants with generalised epilepsy
Summary of findings: needle acupuncture plus valproate showed no clear difference in 50% or greater reduction in seizure frequency ( compared with valproate alone (low certainty).
1 finding from 1 review
Post‐treatment quality of life (QOLIE‐31 score, which has a range of 0‐200, with higher score indicates better quality of life) ( · participants with generalised epilepsy
1 finding from 1 review
Frequency of adverse effects ‐ dizziness ( · participants with generalised epilepsy
Summary of findings: needle acupuncture plus valproate showed no clear difference in frequency of adverse effects ‐ dizziness ( compared with valproate alone (low certainty).
1 finding from 1 review
Frequency of adverse effects ‐ malaise ( · participants with generalised epilepsy
Summary of findings: needle acupuncture plus valproate showed no clear difference in frequency of adverse effects ‐ malaise ( compared with valproate alone (low certainty).
1 finding from 1 review